Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topiramate in Obese Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea
NCT00231634Phase 3Terminated
- Sponsor
- Johnson & Johnson
- Start
- May 2001
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of topiramate in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by Johnson & Johnson. Primary endpoints: Percent change in body weight from baseline at 52 weeks and Change in Hemoglobin A1c from baseline at 52 weeks. Started May 2001; status: terminated.
02
Drugs
topiramate
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT00231634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00231634.